CTOs on the Move

Genus Software Inc

www.genussoft.com

 
Genus Software Inc is a Cupertino, CA-based company in the Software and Internet sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.genussoft.com
  • 10080 N Wolfe Rd Ste sw3301
    Cupertino, CA USA 95014
  • Phone: 408.257.8722

Executives

Name Title Contact Details

Similar Companies

Blue Habanaro

Blue Habanaro, Inc. is a Mississauga, ON-based company in the Software and Internet sector.

SA Technologies Inc

SA Technologies Inc is a Santa Clara, CA-based company in the Software and Internet sector.

Informz

Informz is a Saratoga Springs, NY-based company in the Software and Internet sector.

Memebox Corporation

Memebox, was originally founded in 2012, in Korea as a cosmetic subscription service. It is now a multi-vertical e-commerce platform that delivers 1500 beauty brands;; Memestar, a fashion platform that strives for comprehensive beauty through style ; and I`M Meme, Pony Effect, Bon Vivant, and Nooni which are all Memebox-powered cosmetics brands developed by in-house by our proprietary data engine and R&D Teams. Memebox aims to broaden the concepts and principles of K-Beauty innovation to the world, by the simple action of making people smile.

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.